drugset / Trial / NCT07398417
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
Timeline
- Start
- 2026-01-14
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AXS-14 | Unknown | — | Oral |